Home | My Profile | Contact Us
Research Trends Products  |   order gateway  |   author gateway  |   editor gateway  
Register | Forgot Password

Author Resources
 Author Gateway
 Article submission guidelines

Editor Resources
 Editor/Referee Gateway

 Regional Subscription Agents/Distributors
Current Topics in Pharmacology   Volumes    Volume 7  Issue 1
Skin immune downregulators: from bench to bedside
G. E. Piérard, C. Piérard-Franchimont
Pages: 109 - 116
Number of pages: 8
Current Topics in Pharmacology
Volume 7  Issue 1

Copyright © 2003 Research Trends. All rights reserved


New generations of topical skin immune downregulators (SIDRs) were recently introduced as an alternative to glucocorticoids for the topical treatment of some inflammatory dermatoses.  Tacrolimus, pimecrolimus, sirolimus and dunaimycins inhibit the transcription of proinflammatory cytokine genes through binding to specific immunophilins.  Taken together, SIDRs are able to inhibit a number of pro-inflammatory mediator systems and inflammatory cells with major importance for several cutaneous dermatitides.  Therefore this group of compounds targeted dermatological diseases from the beginning of drug development.  Several clinical trials have demonstrated the efficacy of tacrolimus and pimecrolimus in treating moderate to severe atopic dermatitis.  Psoriasis, contact dermatitis and other dermatoses could also be indications for SIDRs.  This review presents the cell biology changes and the mode of action of SIDRs.  Their pharmacokinetics, clinical results and site effects are compared.

Buy this Article


Buy this article
Buy this volume
Subscribe to this title
Shopping Cart

Quick Links
Search Products
Browse in Alphabetical Order : Journals
Browse by Subject Classification : Journals

Ordering Information Ordering Information
Downloadable forms Downloadable Forms